These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Reply to Dr. Katsanos et al.'s letter. Marticorena-Álvarez P; Chaparro M; Pérez-Casas A; Gisbert JP J Crohns Colitis; 2013 Feb; 7(1):e23-4. PubMed ID: 22921467 [No Abstract] [Full Text] [Related]
7. Reply to Drs. Park & Shin's letter. Marques IN J Crohns Colitis; 2013 Aug; 7(7):601. PubMed ID: 23332559 [No Abstract] [Full Text] [Related]
8. Letter: should immunosuppressive therapy be started with adalimumab in Crohn's disease? Authors' reply. Reenaers C; Louis E; Belaiche J; Seidel L; Keshav S; Travis S Aliment Pharmacol Ther; 2013 Apr; 37(7):752-3. PubMed ID: 23458531 [No Abstract] [Full Text] [Related]
9. Editorial: a clinical decision tool to identify patients who might benefit most from intensified dosing in the biological era-getting nearer? Authors' reply. Dulai PS Aliment Pharmacol Ther; 2020 Apr; 51(7):738-739. PubMed ID: 32162371 [No Abstract] [Full Text] [Related]
10. Editorial: real-world short-term effectiveness of ustekinumab in 305 patients with Crohn's disease-results from the ENEIDA registry. Authors' reply. Iborra M; Beltrán B; Nos P Aliment Pharmacol Ther; 2019 Sep; 50(5):600-601. PubMed ID: 31414541 [No Abstract] [Full Text] [Related]
11. Letter: comparative safety and efficacy of infliximab vs. adalimumab in Crohn's disease - should one consider disease location? Authors' reply. Narula N; Reinisch W Aliment Pharmacol Ther; 2016 Oct; 44(7):772-3. PubMed ID: 27593431 [No Abstract] [Full Text] [Related]
12. Editorial: relative efficacy of infliximab and adalimumab in Crohn's disease in an Australian and New Zealand cohort - authors' reply. Radford-Smith GL; Hartnell F; Doecke JD Aliment Pharmacol Ther; 2017 Mar; 45(6):856-857. PubMed ID: 28211631 [No Abstract] [Full Text] [Related]
13. Ustekinumab in Treatment of Refractory Paediatric Crohn Disease. Cameron FL; Garrick V; Russell RK J Pediatr Gastroenterol Nutr; 2016 Mar; 62(3):e30. PubMed ID: 26910458 [No Abstract] [Full Text] [Related]
14. Anti chimeric antibodies against chimeric monoclonal antibodies may result in Kounis hypersensitivity associated acute coronary syndrome. Mazarakis A; Tsigkas G; Soufras GD; Kounis NG J Crohns Colitis; 2012 Jun; 6(5):632-3. PubMed ID: 22398073 [No Abstract] [Full Text] [Related]
15. [Anti-TNF agents, the class of drugs that promotes treatment for Crohn disease]. Michetti P Rev Med Suisse; 2008 Jan; 4(141):187-8. PubMed ID: 18335883 [No Abstract] [Full Text] [Related]
16. [Vedolizumab in Crohn Disease genesis-sefh drug evaluation report]. González Chávez J; Asensi Diez R; Tamayo Bermejo R; Alegre Del Rey EJ; Martínez López de Castro N Farm Hosp; 2015 Sep; 39(5):297-308. PubMed ID: 26546942 [No Abstract] [Full Text] [Related]
17. GAIN for loss: adalimumab for infliximab-refractory Crohn disease. Mannon P Ann Intern Med; 2007 Jun; 146(12):888-90. PubMed ID: 17577009 [No Abstract] [Full Text] [Related]
18. Angioedema occurring in pediatric patients with Crohn disease treated with adalimumab. Adamiak T; Stephens M; Werlin SL J Pediatr Gastroenterol Nutr; 2010 Aug; 51(2):223-5. PubMed ID: 20410840 [No Abstract] [Full Text] [Related]
19. Blocking lymphocyte adhesion: new treatment for sticky cases of Crohn disease? Rhee SJ; Bousvaros A J Pediatr Gastroenterol Nutr; 2003 Aug; 37(2):211-3. PubMed ID: 12916502 [No Abstract] [Full Text] [Related]
20. Drug-induced lupus associated with infliximab and adalimumab in an adolescent with Crohn disease. Zella GC; Weinblatt ME; Winter HS J Pediatr Gastroenterol Nutr; 2009 Sep; 49(3):355-8. PubMed ID: 19516196 [No Abstract] [Full Text] [Related] [Next] [New Search]